Johnson & Johnson (NYSE:JNJ) Shares Down 1.6% – Time to Sell?

Johnson & Johnson (NYSE:JNJ)’s share price dropped 1.6% during mid-day trading on Tuesday. The company traded as low as $265.28 and last traded at $266.1040. 6,454,019 shares traded hands during trading, a decline of 19% from the average daily volume of 7,943,411 shares. The stock had previously closed at $270.56.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: At the TCT 2026 meeting, real-world analyses of 1,379 patients treated with Impella during high-risk coronary procedures showed lower mortality than in a prior study. A separate report cited a 94% success rate. The findings could support adoption of J&J’s heart-pump business, though further evidence is expected from the ongoing PROTECT IV trial. Article: What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Positive Sentiment: ETFs purchased $35.1 million of JNJ shares on Oct. 29, a modest indication of institutional demand. Article: ETFs Are Buying Johnson & Johnson
• Neutral Sentiment: JNJ has drawn increased investor attention, but the Zacks article provides no specific new forecast or company development to explain the interest. Article: Is Trending Stock Johnson & Johnson a Buy Now?
• Negative Sentiment: One analysis questions whether the shares are fully valued after a strong recent and longer-term advance. That debate could temper investor enthusiasm even as the Impella data adds to the company’s growth story. Article: Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Royal Bank Of Canada cut their target price on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Sanford C. Bernstein set a $270.00 target price on shares of Johnson & Johnson in a research note on Thursday, October 15th. Morgan Stanley cut their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Finally, Weiss Ratings lowered Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson Trading Down 1.6%

The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average price is $265.74 and its 200 day moving average price is $247.22. The stock has a market cap of $640.59 billion, a P/E ratio of 40.32, a PEG ratio of 2.68 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 64,515 shares of company stock valued at $17,271,766. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of large investors have recently added to or reduced their stakes in JNJ. Wellington Management Group LLP boosted its stake in shares of Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares during the last quarter. Amundi raised its stake in shares of Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after acquiring an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth approximately $1,967,399,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.